NASD · Healthcare · Biotechnology · Ireland
Jazz Pharmaceuticals plc is a large cap company (market value between $10 billion and $200 billion) in the Biotechnology industry.
Jazz Pharmaceuticals is a global biopharmaceutical company developing medicines for rare diseases, including epilepsies, cancers, and sleep disorders. Its marketed products include Xywav for narcolepsy and idiopathic hypersomnia, Epidiolex for seizure disorders, and several cancer therapies including Ziihera, Modeyso, Zepzelca, and Rylaze. The company sells its medicines in countries around the world.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Jazz Pharmaceuticals plc stock.
Overvalued: intrinsic value $89.49 per share, market price $208.43, margin of safety -132.9% (as of 2026-10-19).
Its through-the-cycle earnings (17.1% median margin), capitalised at 7.2% with no growth, values the shares at $89.49; the price of $208.43 is 133% above that value.
Leak Score: 48/100 on 10 of 12 signals (On Watch).
17 more funds hold it; the full list is part of the paid plan.
63 more in this industry show a wider margin of safety.
JAZZ is overvalued (as of the 2026-10-19 close). Its through-the-cycle earnings (17.1% median margin), capitalised at 7.2% with no growth, values the shares at $89.49; the price of $208.43 is 133% above that value.
$89.49 per share (as of the 2026-10-19 close), against a market price of $208.43. That is a margin of safety of -132.9%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
48 out of 100, which we rate "On Watch", on 10 of 12 value investing signals.